1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Reapplix Eyes US Market With Trial Results For Wound-Healing Tech

 
• By Catherine Longworth

Following the presentation of results from a randomized trial, Reapplix is ramping up its commercial operations with the hire of a new US president to lead sales of its wound-healing platform, LeucoPatch.

Wound-therapy specialist Reapplix APS says it's moving forward with US commercial activities to support its LeucoPatch wound-healing platform now that the results of a randomized trial assessing LeucoPatch to treat hard-to-treat diabetic foot ulcers are public. The results were presented at the American Diabetes Association 78th Scientific Sessions meeting in Orlando. 

LeucoPatch, marketed in the US as 3CPatch, is a novel platform technology that provides cells and growth factors concentrated from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Johnson & Johnson MedTech: How To Scale Digital Solutions

 
• By Natasha Barrow

J&J's EMEA head of digital solutions, Julia Fishman, talks about the major hurdles in scaling digital innovation, tips for clinical adoption and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

J&J MedTech Launches KINCISE 2 Surgical Automated System In US

 
• By Natasha Barrow

The KINCISE 2 Surgical Automated System aims to “reduce the physical burden on surgeons compared to manual impaction in primary and revision hip and revision knee replacement procedures,” said J&J MedTech.

Abbott Launches Next-Gen Delivery System For Proclaim DRG Neurostim

 
• By Shubham Singh

Allen Burton, Abbott’s medical director of neuromodulation told Medtech Insight that the delivery system was developed to make the procedure easier for physicians, especially those who perform the implantations infrequently.